Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 178

1.

Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.

Chan SL, Wong CH, Lau CP, Zhou Q, Hui CW, Lui VW, Ma BB, Chan AT, Yeo W.

Cancer Chemother Pharmacol. 2013 Jun;71(6):1417-25. doi: 10.1007/s00280-013-2139-4. Epub 2013 Apr 2.

PMID:
23546591
[PubMed - indexed for MEDLINE]
2.

Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.

Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U, Nashan B, Jücker M.

Mol Cancer. 2012 Nov 20;11:85. doi: 10.1186/1476-4598-11-85.

PMID:
23167739
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.

Zhou Q, Lui VW, Lau CP, Cheng SH, Ng MH, Cai Y, Chan SL, Yeo W.

Biochem Pharmacol. 2012 May 1;83(9):1146-58. doi: 10.1016/j.bcp.2012.01.013. Epub 2012 Jan 20.

PMID:
22285225
[PubMed - indexed for MEDLINE]
4.

Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.

Wang C, Gao D, Guo K, Kang X, Jiang K, Sun C, Li Y, Sun L, Shu H, Jin G, Sun H, Wu W, Liu Y.

BMC Cancer. 2012 May 4;12:166. doi: 10.1186/1471-2407-12-166.

PMID:
22559167
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

SB365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of PI3K/Akt/mTOR signaling pathway.

Hong SW, Jung KH, Lee HS, Choi MJ, Son MK, Zheng HM, Hong SS.

Cancer Sci. 2012 Nov;103(11):1929-37. doi: 10.1111/j.1349-7006.2012.02409.x. Epub 2012 Sep 25. Erratum in: Cancer Sci. 2013 Oct;104(10):1389.

PMID:
22909393
[PubMed - indexed for MEDLINE]
6.

HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.

Jung KH, Choi MJ, Hong S, Lee H, Hong SW, Zheng HM, Lee HS, Hong S, Hong SS.

Cancer Lett. 2012 Mar 28;316(2):187-95. doi: 10.1016/j.canlet.2011.10.037. Epub 2011 Nov 4.

PMID:
22182943
[PubMed - indexed for MEDLINE]
7.

The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.

Gedaly R, Angulo P, Chen C, Creasy KT, Spear BT, Hundley J, Daily MF, Shah M, Evers BM.

Anticancer Res. 2012 Jul;32(7):2531-6.

PMID:
22753710
[PubMed - indexed for MEDLINE]
8.

Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.

Charette N, De Saeger C, Lannoy V, Horsmans Y, Leclercq I, Stärkel P.

Mol Cancer. 2010 Sep 22;9:256. doi: 10.1186/1476-4598-9-256.

PMID:
20860815
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Sprengerinin C exerts anti-tumorigenic effects in hepatocellular carcinoma via inhibition of proliferation and angiogenesis and induction of apoptosis.

Zeng KW, Li N, Dong X, Ma ZZ, Jiang Y, Jin HW, Tu PF.

Eur J Pharmacol. 2013 Aug 15;714(1-3):261-73. doi: 10.1016/j.ejphar.2013.04.026. Epub 2013 May 15.

PMID:
23684542
[PubMed - indexed for MEDLINE]
10.

Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.

Wang Z, Zhou J, Fan J, Qiu SJ, Yu Y, Huang XW, Tang ZY.

Clin Cancer Res. 2008 Aug 15;14(16):5124-30. doi: 10.1158/1078-0432.CCR-07-4774.

PMID:
18698030
[PubMed - indexed for MEDLINE]
Free Article
11.

PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.

Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Koch A, Evers BM.

Anticancer Res. 2010 Dec;30(12):4951-8.

PMID:
21187475
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Combined inhibitory effects of celecoxib and fluvastatin on the growth of human hepatocellular carcinoma xenografts in nude mice.

Gao J, Jia WD, Li JS, Wang W, Xu GL, Ma JL, Ge YS, Yu JH, Ren WH, Liu WB, Zhang CH.

J Int Med Res. 2010 Jul-Aug;38(4):1413-27.

PMID:
20926014
[PubMed - indexed for MEDLINE]
13.

The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines.

Ma BB, Lui VW, Hui EP, Lau CP, Ho K, Ng MH, Cheng SH, Tsao SW, Chan AT.

Invest New Drugs. 2010 Aug;28(4):413-20. doi: 10.1007/s10637-009-9269-x. Epub 2009 May 27.

PMID:
19471857
[PubMed - indexed for MEDLINE]
14.

Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.

Zhang DM, Liu JS, Deng LJ, Chen MF, Yiu A, Cao HH, Tian HY, Fung KP, Kurihara H, Pan JX, Ye WC.

Carcinogenesis. 2013 Jun;34(6):1331-42. doi: 10.1093/carcin/bgt060. Epub 2013 Feb 7.

PMID:
23393227
[PubMed - indexed for MEDLINE]
Free Article
15.

Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma.

Hui IC, Tung EK, Sze KM, Ching YP, Ng IO.

Liver Int. 2010 Jan;30(1):65-75. doi: 10.1111/j.1478-3231.2009.02117.x. Epub 2009 Oct 20.

PMID:
19845851
[PubMed - indexed for MEDLINE]
16.

Dual inhibition of PI3K and mTOR signaling pathways decreases human pancreatic neuroendocrine tumor metastatic progression.

Djukom C, Porro LJ, Mrazek A, Townsend CM Jr, Hellmich MR, Chao C.

Pancreas. 2014 Jan;43(1):88-92. doi: 10.1097/MPA.0b013e3182a44ab4.

PMID:
24263107
[PubMed - indexed for MEDLINE]
17.

ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft.

Jasinghe VJ, Xie Z, Zhou J, Khng J, Poon LF, Senthilnathan P, Glaser KB, Albert DH, Davidsen SK, Chen CS.

J Hepatol. 2008 Dec;49(6):985-97. doi: 10.1016/j.jhep.2008.08.010. Epub 2008 Oct 1.

PMID:
18930332
[PubMed - indexed for MEDLINE]
18.

Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.

Ewald F, Grabinski N, Grottke A, Windhorst S, Nörz D, Carstensen L, Staufer K, Hofmann BT, Diehl F, David K, Schumacher U, Nashan B, Jücker M.

Int J Cancer. 2013 Nov;133(9):2065-76. doi: 10.1002/ijc.28214. Epub 2013 May 29.

PMID:
23588885
[PubMed - indexed for MEDLINE]
19.

RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma.

Huynh H, Chow KH, Soo KC, Toh HC, Choo SP, Foo KF, Poon D, Ngo VC, Tran E.

J Cell Mol Med. 2009 Jul;13(7):1371-80. doi: 10.1111/j.1582-4934.2008.00364.x. Epub 2008 May 7.

PMID:
18466352
[PubMed - indexed for MEDLINE]
20.

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk